BeOne Newsroom
Media Resources
Corporate Press Kits
Review resources about BeOne, formerly BeiGene.
Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.
Media Library
View and download images of our leaders, facilities, company logo and other corporate assets.
Press Releases
Read our latest news.
-
December 23, 2025
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
December 18, 2025
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
-
December 8, 2025
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
-
December 7, 2025
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
-
November 26, 2025
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
-
November 20, 2025
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
-
November 17, 2025
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
-
November 6, 2025
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates — Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to…
-
October 28, 2025
BeOne Medicines to Present at Upcoming Investor Conferences — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it…
-
October 22, 2025
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its…
-
October 20, 2025
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 — New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in…
-
October 13, 2025
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA — Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory…
Congress Hub
Review the latest information about the data we’re presenting and where you can find us.
Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More
Our Pipeline
Our broad and deep cancer pipeline is one of the largest in the industry.